Cancer Vaccines
Dynavax Provides 2007 Financial Outlook
Published in Hepatitis Weekly, March 12th, 2007
The following statements are forward-looking and are based on current expectations. Actual results may differ materially. Except as expressly set forth below, these statements do not include the potential impact of any equity offerings, new business collaborations or other transactions that may be closed or entered into after February 23, 2007.
The company's consolidated cash, cash equivalents, marketable securities and investments held by Symphony Dynamo, Inc. (SDI), or total cash, were $86 million at the beginning of 2007. Total cash will increase by $30...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
Source: Hepatitis Weekly (2007-03-12)
More Articles from Hepatitis Weekly
- Cancer Vaccines
Dynavax Initiates Phase I Trial of Hepatitis B Therapy - Hepatitis
Idenix Pharmaceuticals Reports Fourth Quarter and Year End Financial Results - Hepatitis B Virus
SEBIVO (Telbivudine) Approved in China as New Treatment Option for Patients with Chronic Hepatitis B - Hepatitis C Virus
Human Genome Sciences Announces Positive Interim Results of Phase 2b Trial of Albuferon With Ribavirin in Treatment-Naive Patients With Chronic Hepatitis C - Hepatitis C Virus
Human Genome Sciences Initiates Phase 3 Clinical Trial of Albuferon With Ribavirin in Treatment-Naive Patients With Chronic Hepatitis C Genotypes 2 and 3 - HIV/AIDS
Hepatitis Foundation International: New Study Supports Effectiveness of Liver Wellness Education - More from this issue of Hepatitis Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
